Kartesada (Pregabalin)

Pregabalin binds to the α2‑δ subunit of voltage‑gated calcium channels in the central nervous system, reducing calcium entry into nerve terminals. This limits the release of excitatory neurotransmitters, which helps dampen abnormal neuronal firing that underlies pain, seizures, and anxiety.

The specific dose of Kartesada is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, renal function, and other factors. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for pregabalin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kartesada contains the same active ingredient, pregabalin, as other branded or generic gabapentinoids. Its efficacy and safety profile are comparable, but differences may exist in formulation, excipients, and regulatory approvals, which can influence prescribing preferences and availability in specific markets.

Store Kartesada at ambient temperature below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Kartesada is taken orally, usually with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious risks include severe allergic reactions such as angioedema, life‑threatening skin conditions like Stevens‑Johnson syndrome, suicidal thoughts or behaviors, and respiratory depression when combined with opioids or other central nervous system depressants. Prompt medical attention is required if any of these occur.

Kartesada is contraindicated in patients with known hypersensitivity to pregabalin or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled heart failure, or those taking medications that may cause dangerous additive CNS depression.